Swiss pharmaceutical group, Helsinn, has revealed it will be investing €6 million at its drug product supply centre (Helsinn Birex Pharmaceuticals — HBP) in Dublin, Ireland, to safeguard its supply chain and compliance with regulatory requirements worldwide.
Euros
This investment will provide HBP with the capability to apply unique serial numbers and tamper evidence features that meet the requirements of the US Drug Quality and Security Act (DQSA), the EU falsified medicines directive (FMD) and other local requirements in markets where the company’s products are sold.
“The presence of counterfeit medicines in the global pharmaceutical supply chain denotes a clear and present threat to patient safety, fraud against healthcare payers and a global reputational risk to the industry,” revealed Giorgio Calderari, HelsinnGroup general manager & chief operating officer. “This major investment by Helsinn reinforces our commitment to patients worldwide, who deserve assurance that they are receiving authentic Helsinn products, developed, manufactured and supplied by our team of professional staff.”
Padraig Somers, Helsinn Birex Local general manager, commented: “Detecting and eliminating counterfeit medicines from the pharmaceutical supply chain is a major challenge for our industry. This initiative ensures that Helsinn Birex’s reputation for world-class quality products is enhanced going forward for the benefits of our patients as well as Helsinn.”